Edgewise Therapeutics, Inc.

EWTXReported to SECin USCIK 0001710072Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 64. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 64
Form 4 lines at Edgewise Therapeutics, Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Russell Alan JChief Scientific OfficerAwardnothing paid65,000 sharesAug 17, 2026Russell Alan JChief Scientific Officernothing paidAward · Aug 17Award65,000Aug 17, 2026
Derakhshan BehradChief Business OfficerAwardnothing paid100,000 sharesAug 17, 2026Derakhshan BehradChief Business Officernothing paidAward · Aug 17Award100,000Aug 17, 2026
Nofi MichaelChief Financial OfficerAwardnothing paid48,750 sharesAug 17, 2026Nofi MichaelChief Financial Officernothing paidAward · Aug 17Award48,750Aug 17, 2026
Donovan Joanne M.CMOAwardnothing paid65,000 sharesAug 17, 2026Donovan Joanne M.CMOnothing paidAward · Aug 17Award65,000Aug 17, 2026
MOORE JOHN RGeneral CounselAwardnothing paid65,000 sharesAug 17, 2026MOORE JOHN RGeneral Counselnothing paidAward · Aug 17Award65,000Aug 17, 2026